Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

· Issued by Amylyx Pharmaceuticals, Inc. via Business Wire

Summary by 6ix AI

Amylyx Pharmaceuticals, a company developing investigational therapies for endocrine conditions and neurodegenerative diseases, said its management will take part in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 9:30 a.m. ET.

Key details

  • A live webcast will be available in the Events and Presentations area of the Investor section of the company's website, with a replay available for 90 days afterward.

6ix AI wrote this summary from the release below and checked it against the release.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, September 30th, 2026, at 9:30 a.m. ET.

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

View original source (Business Wire)Amylyx Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from Amylyx Pharmaceuticals

Later from Amylyx Pharmaceuticals

All Amylyx Pharmaceuticals news releases